 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
TBIO stock results show that Telesis Bio missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of...

TBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q4 2023

SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced...

Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results

Gagnants
L'action Genelux (NASDAQ:GNLX) a mont vendredi de 10,06% 7 dollars lors de la session after-market.
L'action Telesis Bio (NASDAQ:TBIO) a mont de 9,28% 0,60 dollars.
Le titre Estrella...

12 titres de soins de sant  en mouvement lors de la session apr s-cl ture le 08/03/2024

Titoli in rialzo
Le azioni di Genelux (NASDAQ:GNLX) hanno fatto segnare +10,06% a 7 dollari durante la sessione after-market di venerd .
Il titolo Telesis Bio (NASDAQ:TBIO) ha avuto un aumento del...

12 titoli sanitari in movimento, after-market del 08/03/2024

Telesis Bio, Inc. (NASDAQ:TBIO  Get Free Report) was the target of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 131,400 shares...

Telesis Bio, Inc. (NASDAQ:TBIO) Sees Large Decline in Short Interest

Telesis Bio announces Q4 and full-year 2023 select preliminary financial results, highlighting strong BioXp kit sales, expanding gross margin and reduced expenseSAN DIEGO, Feb. 26, 2024 (GLOBE...

Telesis Bio Announces Select Preliminary  Fourth Quarter 2023 Financial Results

Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The firm also focuses on providing applications to enable researchers to rapidly, accurately, and reproducibly build or write synthetic DNA and mRNA and short oligonucleotides such as CRISPR guides that are ready to use in many downstream synthetic biology enabled markets. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.

Volume (M)	15,323.00
52-Wk High	$3.01
52-Wk Low	$0.30

TBIO Translate Bio, Inc.

About

Feed

News

Earnings

Fundamentals